Interestingly, a retrospective study performed on biopsy samples analysis from triple negative breast cancer indicated that CREB3L1 levels in tumors responsive to doxorubicin chemotherapy were significantly higher than in those resistant to this treatment (Denard et al., 2018). This evidence concerns the gene CREB3L1 and triple-negative breast carcinoma.